ExpressDetect®

Mitch Sanders, CEO

June 2009

ECI Biotech

ECI Biotech is a premier developer of ExpressDetect® Diagnostics.

ExpressDetect® Diagnostics are simple, inexpensive, rapid, and safe.

ECI has development agreements with industry leaders in Consumer and Professional Health Care.

ECI Biotech has secured an aggregate of $18M in development funding, grants, and private equity.

June 2009

Funding History

Equity Financing $7.5 M

Collaborative Seed and Growth Partners, LLC

Vik Brothers International

The GS Fuller Foundation

Corporate Development Funding $5.0 M

Grants Phase I and II SBIR $1.9 M

June 2009

Current FundingCurrent Funding

Corporate Development Funding

Current $1M

SBIR Grants Project AwardedYeast Diagnostic $200,870PoC Wound Diagnostic, Phase I $208,311Therapeutic Agent for Periodontal Disease, years 1+2 $242,072PoC Wound Diagnostic, Phase II $949,000

Project PendingDetecting Trauma Induced Wound Infections $689,000Yeast Diagnostic Phase II $1,000,000Theranostic Grant $269,000

June 2009

QuickTime™ and aTIFF (Uncompressed) decompressorare needed to see this picture.

A series of high impact, low-cost, fast turnaround assays

ExpressDetect® Technology Summary

QuickTime™ and aTIFF (Uncompressed) decompressorare needed to see this picture.

Wound Care

Oral Care

Women’s Care

UTI

June 2009

Primary Markets

$2.9 B Wound Care Market 9.2% (CAGR)1. PoC for Clinics & Hospitals

2. Dressing sensor (Home health, VA, and nursing homes)

3. Consumer Band aids

4. Military Product for Combat Casualty Care

$2.9 B Oral Care Market (Cleaners/Whiteners/Dentures) 4.9% (CAGR)

1. Consumer Strep Diagnostic

2. Consumer and Professional Gingivitis

3. Consumer and Professional Periodontitis

Partner

Partner

Partner

Partner

June 2009

Secondary Markets

$1 B Women’s Health 16.6% (CAGR)

1. Yeast Diagnostic

2. BV-Tric-Yeast Consumer and Professional Care

$3 B UTI Diagnostic 40% (CAGR)1. Consumer UTI

2. Foley Catheter Market

Partner

Partner

June 2009

reportermolecules

anchor

peptidesubstrate

Diagnostic Assay Formats

Peptide covalently attached to microbead anchor and reporter molecule

PRESENTABSENT

PATCH

PoC QuickTime™ and aTIFF (Uncompressed) decompressor

are needed to see this picture.

June 2009

ExpressDetect® Assay Technology

Interaction Separation Detection

dual affinity tag

peptide

bead bead

minutes

June 2009

Market SizeMarket Size

Advanced Wound Care is a $2.8 B Industry

14M Chronic Wounds Treated Annually

Each patient is checked 8-10 x for infection

Market Opportunity ($840M)

Additional Market (50M Acute Wounds)

Biopsy

Visual exam only

Swab

35%

53%

12%

June 2009

Unmet NeedUnmet Need

Wounds need to be tested for bacterial load before

treatment

Visual Assessment Methods Inaccurate

Current methods take 2-3 days to get results

June 2009

Value PropositionValue Proposition

Our test takes 10 minutes

Low cost $16 (vs. $75 swab or $225 biopsy),

simple, and safe

Next steps, pre IDE meeting, clinical studies, and

launch

1.0E+01

1.0E+02

1.0E+03

1.0E+04

1.0E+05

1.0E+06

1.0E+07

1.0E+08

1.0E+09

1.0E+10

1 10 100 1000 10000

ng peptide clipped (0.1 ml sample)

diabetic

pressure

venous

post-acute

undefined

3.0E+05 CFU/mlcutoff

45 ng peptidecutoff

June 2009

Time Course of Color Reaction

Dressing Sensor Time Course with A. baumannii. In the presence of culture media (BHI) or BHI + A. baumannii incubated for 0, 20, 40, or 60 minutes. Blue color indicates the presence of the pathogen. Scale Bar = 4 cm.

QuickTime™ and aTIFF (LZW) decompressor

are needed to see this picture.

June 2009

Unique FunctionalityUnique Functionality

Inexpensive (COGS<3 cents), and safe enough for

band-aids

Sensor turns blue when infection is likely

June 2009

Proof of ConceptProof of Concept

Detection of Common Wound Pathogens

Threshold is > 106 CFU/mL

Top five bacteria with CPI2S

0

0.5

1

1.5

2

2.5

3

3.5

4

0 100 200 300 400 500

Time (sec)

OD 650 nm

S. aureusP. mirabilisP. aeruginosaE. faecalisS. pyogenesControl

1

10

100

1000

10000

UWI 021UCO 025UWI 023UCO 021UTS 021control

UTS 010UCO 006UCLA 004UWI 008UNC 005

controlUCO 001UCLA 017UCO 002UCO 005UTS 001

controlUTS 013UWI 013UCO 015UWI 011

UCLA 021

controlHUP 079

UMMH 202UMMH 203

control

slope of color change

(mU A405/min)

P. aeruginosa S. aureus E. faecalis S. pyogenes P. mirabilis

June 2009

Intellectual PropertyIntellectual Property

Strong IP with 18 patent families issuing world-

wide

Additional design patents in preparation (See

IP doc)

June 2009

510 (k) and CLIA Guidance510 (k) and CLIA Guidance

Clear regulatory path with FDA

Time for Pre-IDE meetings

June 2009

CompetitionCompetition

ExpressDetect® Antibody Visual Signs CultureReal Time X Specificity X

Low Cost $16 $16+ $75-$225

Broad Spectrum X

Active Detection X ?

June 2009

RevenueRevenue

Chronic Wound Opportunity for ECI = $840 Million14M wounds; 4 tests/wound; $15/test

2008 2009 2010 2011 2012Revenue (000) 793 515 2,453 12,691 23,859EBITDA (1,049) (2,056) (1,412) 4,474 12,339Pretax/Net Income (1,223) (2,693) (1,706) 4,015 9,146

June 2009

First Institutional RoundFirst Institutional Round

$3M

$2M

$3M

$2M Manufacturing

June 2009

ECI Organization Chart

David FogelCFO

Tara Shariff, MBADir. of Buisness Development

G&A

Barbara AppiahClinical Research

Linsay Poland MSRobotics and HTS Library Specialist

Jennifer EwaltChemistry

Courtney Mayo, Ph.D.Biochemistry and Molecular Scientist

Shelley Doughtery, PhDPolymer Scientist

Andrei Rakitin, PhDPhysicist/Statistics

Geert Cawenbergh, Ph.D.Director of Scientific Advisors & BOD

R&D

VP of China OperationsZhong Zhang

VP of US OperationsDale Macy,

Manufacturing

Mitchell Sanders, PhDCEO and Founder

June 2009

SummarySummary

ExpressDetect®- simple, inexpensive, rapid,

& safe

Large Markets ($BB)

Primary Products in Wound Care

Pipeline (oral care, women’s health, & UTI)

Significant revenue >$50M and liquidity

opportunity